Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.
Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.
The aim of this study is to report our experience with ceftolozane-tazobactam and to evaluate
 its safety and efficacy in the treatment of ICU dependent nosocomial respiratory tract
 infections due to extensively drug resistant Pseudomonas aeruginosa. Different dosing regimes
 of ceftalozane-tazobactam is evaluated and compared to the standard therapy of Colomycin.
Ceftolozane-tazobactam (C/T) is a novel type of beta-lactam/beta-lactamase inhibitor
 antibiotics targeting nosocomial infections caused by Gram-negative bacteria. In recent
 years, ceftolozane-tazobactam was prescribed for treating complicated urinary tract
 infections (cUTI) and complicated intraabdominal infections (cIAI). Following the results of
 ASPECT-NP trial in 2019, it was approved as a therapeutic option in nosocomial pneumonia
 including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

 The drug shows an excellent activity against ESBL-producing Enterobacterales and
 multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Pseudomonas
 aeruginosa. The latter is widely recognized as a common pathogen of nosocomial respiratory
 tract infections.

 There is still a need for observations of clinical experiences to better define the
 risk-benefit profile of ceftolozane-tazobactam. The aim of this study is to report our
 experience with ceftolozane-tazobactam and to evaluate its safety and efficacy in the
 treatment of ICU dependent nosocomial respiratory tract infections due to extensively drug
 resistant Pseudomonas aeruginosa. Different dosing regimes of ceftalozane-tazobactam is
 evaluated and compared to the standard therapy of Colomycin.
Inclusion Criteria:

 -  Hospital-acquired pneumonia caused by extensively drug-resistant Pseudomonas
 aeruginosa

 -  ≥ 72 hours of targeted antibiotic therapy against Pseudomonas aeruginosa with either
 Colomycin or Ceftolozane-Tazobactam

 Exclusion Criteria:

 -  Participation in an interventional trial aiming nosocomial infections

 -  Treatment was not with the intent to cure the infection